Welcome to the Investor Relations page. If you are a member of the investment community with a question about Regeneron, please call our Investor Relations Line at (914) 345-7400.
For an e-mail response to your Regeneron investment question, please contact us at invest@regeneron.com.
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, age-related macular degeneration, and certain cancers. Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic conditions, and cancer.
| Recent Events |
| Aug 13, 2010 |
Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference View Presentation
|
| Jul 15, 2010 |
Regeneron 2010 Investor Day Note: These videos were shown at the meeting but not webcast. You may view them here at any time.
VelociGene® and VelocImmune® Technologies: A Brief History
Process Development and Manufacturing
Introduction: Leonard Schleifer, M.D., Ph.D., Chief Executive Officer
R&D Overview: George Yancopoulos, M.D., Ph.D., Chief Scientific Officer
Early Clinical Development: Neil Stahl, Ph.D., Senior Vice President, Research and Development Sciences
Early Stage Development: Peter Powchik, M.D., Senior Vice President, Clinical Development
Oncology: Alain Thibault, M.D., Vice President, Clinical Sciences, Oncology
VEGF TrapEye: Robert Vitti, M.D., Executive Director, Clinical Sciences, Ophthalmology
ARCALYST® (rilonacept): Bob Terifay, Senior Vice President, Commercial
Financial Overview: Murray Goldberg, Chief Financial Officer
Industrial Operations and Product Supply: Dan Van Plew, Senior Vice President, Industrial Operations and Product Supply
|
|
Stock Information
NASDAQ:REGN
$23.17
+ 0.69
|
Sep 2, 2010
11:30 AM ET |
Quotes delay at least 20min., by eSignal.
Shareholder Tools
Featured Report